Pegvisomant

Pegvisomant is a pharmacotherapy agent used in the treatment of acromegaly, a disorder characterized by excessive growth of the hands, feet, and face, due to overproduction of growth hormone (GH) by the pituitary gland. Pegvisomant acts as a growth hormone receptor antagonist, effectively blocking the effects of growth hormone, and thereby controlling the symptoms associated with acromegaly.

Mechanism of Action

Pegvisomant is a genetically engineered analog of human growth hormone. It binds to the growth hormone receptor on cell surfaces with a higher affinity than natural growth hormone, preventing the latter from exerting its biological effects. Unlike growth hormone, which causes the receptor to activate, pegvisomant blocks the receptor, preventing the downstream effects of growth hormone signaling. This leads to a decrease in the production of Insulin-like Growth Factor 1 (IGF-1), a hormone that mediates many of the growth-promoting effects of growth hormone.

Indications

Pegvisomant is indicated for the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogs did not normalize IGF-1 levels or was not tolerated.

Administration

Pegvisomant is administered as a subcutaneous injection. The dose and frequency of administration depend on the patient's IGF-1 levels and clinical response. Treatment with pegvisomant requires regular monitoring of IGF-1 levels to ensure therapeutic effectiveness and adjust dosing as necessary.

Side Effects

Common side effects of pegvisomant include injection site reactions, liver enzyme elevations, and lipid abnormalities. Less frequently, patients may experience headaches, dizziness, and gastrointestinal symptoms. Severe liver damage is a rare but serious side effect, necessitating regular liver function tests during treatment.

Contraindications

Pegvisomant is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with impaired liver function, and the drug should be used with caution in patients with a history of pituitary tumor.

Pharmacokinetics

Pegvisomant is primarily metabolized in the liver. Its elimination half-life allows for once-daily dosing in most patients. The pharmacokinetics of pegvisomant may be altered in patients with hepatic impairment, requiring dose adjustments.

Clinical Trials

Clinical trials have demonstrated that pegvisomant effectively lowers IGF-1 levels in patients with acromegaly, with a significant proportion of patients achieving normalized IGF-1 levels. These trials have also shown improvements in symptoms and quality of life in treated patients.

Conclusion

Pegvisomant represents a significant advancement in the treatment of acromegaly, offering an effective alternative for patients who do not respond to traditional therapies. Its unique mechanism of action and efficacy in normalizing IGF-1 levels make it a valuable tool in managing this complex endocrine disorder.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian